Ocular Therapeutix Outlines Axpaxli NDA Plan for Q4 2026 with Cash Runway Extending into 2028
Ocular Therapeutix (OCUL) has announced a strategic roadmap following what management described as a transformational year. The company plans to submit a New Drug Application (NDA) for Axpaxli in the fourth quarter of 2026, supported by landmark Phase III superiority results from its SOL-1 study. Financially, the company maintains a strong position with $530.6 million in cash, providing a runway that extends into 2028. This capital buffer is intended to support the regulatory path toward the company's first potential product approval and subsequent commercialization efforts.
Tickers: $OCUL
Topics: clinical trial results earnings call Phase III results regulatory path